Efficiency study of a One-step RT-PCR compared with Real-time RT-PCR for SARS-CoV-2.
Article Sidebar
Main Article Content
Abstract
The COVID-19 pandemic was caused by SARS-CoV-2 infections. RTA-AFRIMS provided real-time reverse transcription polymerase chain reaction (real-time RT-PCR), one of the gold standards for SARS-CoV-2 detection, in response to the pandemic and in support of its military missions and Thai public health. The Cobas Liat SARS-CoV-2 system, which was the first U.S. Food and Drug Administration authorized Point-of-Care RT-PCR test, was claimed to offer highly sensitive and rapid SARS-CoV-2 nucleic acid detection. Considering the potential establishment of this new diagnostic technology in the RTA-laboratory, we evaluated its efficiency, sensitivity, and specificity.
Sixty nasopharyngeal swabs in viral transport medium were tested by both real-time RT-PCR and the Cobas Liat SARS-CoV-2 system. The results from the two procedures were then analyzed for sensitivity and specificity. The results of the two assays showed 100% agreement, for both positive and negative samples, with a correlation level of 0.98. The Point-of-Care Cobas Liat SARS-CoV-2 system produced results concordant with real-time RT-PCR and required less time and processing. Based on this assessment, the system was established in the diagnostic laboratory to support both military and civilian tasks.
Material and Methods: Sixty nasopharyngeal swabs in viral transport medium were tested by real-time RT-PCR and the Cobas Liat SARS-CoV-2 system. The results from the two procedures were then analyzed for sensitivity and specificity.
Results: The results of the two assays showed 100% agreement, both positive and negative, at a correlation level of 0.98.
Conclusion: Point-of-Care Cobas Liat SARS-CoV-2 system produced results concordant with real-time RT-PCR and required less time and processing. Based on this assessment, the system was established in the diagnostic laboratory to support in military and civilian tasks.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
World Health Organization. Advice for the public on COVID-19 – World Health Organization [Internet]. World Health Organization. 2023 [cited 2024 Dec 27]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public?adgroupsurvey=
World Health Organization. WHO Coronavirus (COVID-19) Dashboard.2565 [Internet]. World Health Organization. 2022 [cited 2022 Sep 27]. Available from: https://covid19.who.int/
Department of Desease. [Coronavirus Disease 2019 (COVID-19) Situation in Thailand]. Nontaburi : Ministry of Public Health;2020. Thai. 4. The Medical Council of Thailand. Coronavirus disease (COVID-19) [Internet]. Bangkok; 2019 [cited 2024 Dec 27]. Available from: https://tmc.or.th/covid19/covid19_for_medical.php
Roche Diagnostics. Cobas® SARS-CoV-2 Nucleic acid test for use on the Cobas® Liat® System Document Revision 4.0 [Internet]. Branchburg: Roche Molecular Systems, Inc; 2024 [cited 2024 Dec 21]. Available from: https://diagnostics.roche.com/content/dam/diagnostics/us/en/products/c/cobas-liat-support/sars-cov-2-cova-insert-and-quality-control-kit-insert-eua1.pdf
Poljak M, Korva M, Knap Gašper N, Fujs Komloš K, Sagadin M, Uršič T, et al. Clinical Evaluation of the cobas SARS-CoV-2 Test and a Diagnostic Platform Switch during 48 Hours in the Midst of the COVID-19 Pandemic. J Clin Microbiol. 2020;58(6):e00599-20.
Hansen G, Marino J, Wang ZX, Beavis KG, Rodrigo J, Labog K, et al. Clinical Performance of the Point-of-Care cobas Liat for Detection of SARS-CoV-2 in 20 Minutes: a Multicenter Study. J Clin Microbiol. 2021;59(2):e02811-20.